06
FEB
2024

Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification

Posted By :
Comments : Off
Accompanied by Broad Patent Coverage BETHESDA, MD, February 6, 2024 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the key development work for the Flaskworks manufacturing system has been completed and an external vendor has been engaged to produce GMP-grade units of the system. In addition, the patent coverage of the...
Read More
21
DEC
2023

Northwest Biotherapeutics Announces that a Marketing Authorization Application has been Submitted to the UK MHRA For DCVax®-L for Glioblastoma

Posted By :
Comments : Off
Culmination Of Over 20 Years Of Research And Clinical Development BETHESDA, MD, December 21, 2023 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that a Marketing Authorization Application (MAA) was submitted yesterday to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for DCVax®-L for glioblastoma...
Read More
22
NOV
2023

Northwest Biotherapeutics Provides Update On Final Preparations for Marketing Authorization Application

Posted By :
Comments : Off
BETHESDA, MD, November 22, 2023 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, provided an update today about the final preparations for the Marketing Authorization Application (MAA) that will be submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA)(the equivalent of the U.S. FDA) in the U.K. for commercial approval...
Read More
13
OCT
2023

Northwest Biotherapeutics Provides Update on Near Term Plans for Submission of Marketing Authorization Application

Posted By :
Comments : Off
BETHESDA, MD, October 13, 2023 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, provided an update today about its progress toward submission of a Marketing Authorization Application (MAA) to the Medicines and Healthcare Products Regulatory Agency (MHRA)(the equivalent of the U.S. FDA) in the U.K. for commercial approval of the Company’s...
Read More
12
SEP
2023

Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company’s Scientific Advisory Board

Posted By :
Comments : Off
BETHESDA, MD, September 12, 2023 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announces that Dr. Linda Liau, MD, PhD, MBA has joined the Company’s Scientific Advisory Board (SAB). Dr. Liau served as the Principal Investigator of the Phase 3 trial of DCVax®-L for treatment of glioblastoma. She is Chair of the Department of Neurosurgery at...
Read More